Sign up to save your podcasts
Or
Share Eylea HD Approved for RVO and Extended Dosing
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eylea HD Approved for RVO and Extended Dosing
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Eyewire NewsEylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.
Learn more about your ad choices. Visit megaphone.fm/adchoices